Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
MENLO PARK, Calif., Oct. 25, 2017 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2017, on Wednesday, November 1, 2017, after the market close. Geron’s management will also host a conference call for analysts and investors on Wednesday, November 1, 2017, at 4:30 p.m. Eastern Time to discuss the company’s third quarter results and recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 1056465. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at https://edge.media-server.com/m6/p/25tyxgih or at www.geron.com on the Investors pages, under Events. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through December 1, 2017.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
